FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma

FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell carcinoma.

Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news